David J Maron
Affiliation: Vanderbilt University
- Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trialDavid J Maron
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Arch Intern Med 163:1448-53. 2003..Our objective was to study the impact of a theaflavin-enriched green tea extract on the lipids and lipoproteins of subjects with mild to moderate hypercholesterolemia...
- Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?David J Maron
Kim Dayani Center for Health Promotion at Vanderbilt University, Nashville, TN, USA
Nat Clin Pract Cardiovasc Med 1:18-9. 2004
- Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?David J Maron
Vanderbilt Heart and Vascular Institute, 1215 21st Ave South, MCE 5th Floor South Tower, Nashville, TN, 37232 8800, USA
Curr Treat Options Cardiovasc Med 13:16-25. 2011..Successful translation of COURAGE OMT to everyday practice will require a health care system that rewards quality of care...
- Impact of Adding Ezetimibe to Statin to Achieve Low-Density Lipoprotein Cholesterol Goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] Trial)David J Maron
Vanderbilt University School of Medicine, Nashville, Tennessee Electronic address
Am J Cardiol 111:1557-62. 2013..In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy...
- Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologistsDavid J Maron
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
Am Heart J 162:1034-1043.e13. 2011....
- Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
J Am Coll Cardiol 58:131-7. 2011..Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary artery disease (CAD)...
- Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron
Departments of Medicine and Emergency Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 8800, USA
J Am Coll Cardiol 55:1348-58. 2010..This paper describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors...
- Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron
Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Am J Cardiol 104:1055-62. 2009..6 years or worse angina at 1 year, but it was associated with a high rate of crossover to revascularization...
- Health-risk appraisal with or without disease management for worksite cardiovascular risk reductionDavid J Maron
Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, and Medical Director, Dayani Center for Health and Wellness, Vanderbilt University Medical Center, Nashville, Tennessee, USA
J Cardiovasc Nurs 23:513-8. 2008..Our objective was to determine how the intensity of intervention after HRA affected cardiovascular risk after 1 year, comparing individual follow-up counseling with environmental supports...
- Flavonoids for reduction of atherosclerotic riskDavid J Maron
Vanderbilt Page Campbell Heart Institute, Vanderbilt University Medical Center, 2311 Pierce Avenue, Nashville, TN 37232 8802, USA
Curr Atheroscler Rep 6:73-8. 2004..Although there are no recommended daily intake goals for flavonoids, the data presented provide additional rationale to eat a diet containing a variety of flavonoid-rich foods and beverages...
- Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studiesSean P Collins
Vanderbilt University, Nashville, TN, USA
Am Heart J 164:825-34. 2012..Methods for identifying patients that can be sent home early are lacking. Improving the physician's ability to identify and safely manage low-risk patients is essential to avoiding unnecessary use of hospital beds...
- A comparison of criterion standard methods to diagnose acute heart failureSean P Collins
Department of Emergency Medicine, Vanderbilt University, Nashville, TN 37232, USA
Congest Heart Fail 18:262-71. 2012..Different criterion standards identify different patients from among those being evaluated for AHFS. Researchers should consider this when choosing between the various criterion standard approaches when evaluating new index tests...
- Therapeutic procedures for coronary vasospasm-induced polymorphic ventricular tachycardiaWilliam F Dresen
Vanderbilt University Medical Center, 905 Derby Trace, Nashville, TN 37211, USA
Ther Adv Cardiovasc Dis 6:115-21. 2012..Furthermore, consideration of an implantable cardioverter defibrillator is warranted when vasospasm is complicated by lethal ventricular arrhythmias...
- Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsMichael H Davidson
Radiant Development, Chicago, Illinois, USA
Am J Cardiol 96:556-63. 2005..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
- Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology IILuther T Clark
State University of New York Downstate Medical Center, Brooklyn, NY, USA
J Gen Intern Med 21:320-6. 2006..Additional research is needed to elucidate reasons for this disparity and to evaluate strategies for improving goal achievement among AA patients receiving therapy for dyslipidemia...
- Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424William E Boden
VA Connecticut Healthcare System, West Haven, CT, USA
Am Heart J 151:1173-9. 2006....
- The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialWilliam E Boden
VA Connecticut Healthcare System, West Haven, Connecticut, USA
Am J Cardiol 99:208-12. 2007....
- Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudyLeslee J Shaw
Emory University School of Medicine, Atlanta, GA 30306, USA
Circulation 117:1283-91. 2008....
- Optimal medical therapy with or without PCI for stable coronary diseaseWilliam E Boden
Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
N Engl J Med 356:1503-16. 2007....